Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | CTSK | P43235 | 6/20 | 0.47 |
| ▸ | PPARA | Q07869 | 5/20 | 0.47 |
| ▸ | PPARG | P37231 | 4/20 | 0.47 |
| ▸ | ACE | P12821 | 1/20 | 0.47 |
| ▸ | PPARD | Q03181 | 2/20 | 0.46 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.44 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.44 |
| ▸ | CTSS | P25774 | 3/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
| ▸ | JAK3 | P52333 | 1/20 | 0.43 |
| ▸ | BTK | Q06187 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28821322 | 1.00 | ALDH1A1 (0.48) | ALDH1A1TSHRCTSKPPARAPPARG | |
| SCHEMBL955903 | 1.00 | ALDH1A1 (0.48) | ALDH1A1TSHRCTSKPPARAPPARG | |
| SCHEMBL20562067 | 0.97 | ALDH1A1 (0.50) | ALDH1A1TSHRCTSKPPARAPPARG | |
| SCHEMBL20562065 | 0.97 | ALDH1A1 (0.50) | ALDH1A1TSHRCTSKPPARAPPARG | |
| SCHEMBL31028252 | 0.93 | CTSK (0.47) | ALDH1A1TSHRCTSKPPARAPPARG | |
| SCHEMBL31306238 | 0.93 | PPARA (0.49) | ALDH1A1TSHRCTSKPPARAPPARG | |
| SCHEMBL31228403 | 0.93 | PPARA (0.49) | ALDH1A1TSHRCTSKPPARAPPARG | |
| SCHEMBL952620 | 0.87 | CTSK (0.48) | CTSKPPARACTSS | |
| SCHEMBL952619 | 0.87 | CTSK (0.48) | CTSKPPARACTSS | |
| SCHEMBL15699370 | 0.87 | CTSK (0.48) | CTSKPPARACTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114929705-A | MLL1 inhibitor and anticancer agent | 诺华公司 | 2022-08-19 | — | — | CN | disclosed |
| US-9278997-B2 | Processes for the manufacture of macrocyclic depsipeptides and new intermediates | NOVARTIS AG (CH) | 2016-03-08 | — | — | US | disclosed |
| US-20140080995-A1 | Processes for the Manufacture of Macrocyclic Depsipeptides and New Intermediates | NOVARTIS AG (CH) | 2014-03-20 | — | — | US | disclosed |
| US-8669266-B2 | Quinoline-carboxamide derivatives as P2Y12 antagonists | SANOFI (FR) | 2014-03-11 | — | — | US | disclosed |
| EP-2699585-A1 | PROCESSES FOR THE MANUFACTURE OF MACROCYCLIC DEPSIPEPTIDES AND NEW INTERMEDIATES | Novartis AG (CH) | 2014-02-26 | — | — | EP | disclosed |
| US-8614289-B2 | Processes for the manufacture of macrocyclic depsipeptides and new intermediates | NOVARTIS AG (CH) | 2013-12-24 | — | — | US | disclosed |
| US-8426420-B2 | Heterocyclic pyrazole-carboxamidesas P2Y12 antagonists | SANOFI (FR) | 2013-04-23 | — | — | US | disclosed |
| US-20120277406-A1 | Processes for the Manufacture of Macrocyclic Depsipeptides and New Intermediates | NOVARTIS AG (CH) | 2012-11-01 | — | — | US | disclosed |
| WO-2012143888-A1 | PROCESSES FOR THE MANUFACTURE OF MACROCYCLIC DEPSIPEPTIDES AND NEW INTERMEDIATES | NOVARTIS AG (CH) | 2012-10-26 | — | — | WO | disclosed |
| EP-2238128-B1 | HETEROCYCLIC PYRAZOLE-CARBOXAMIDES AS P2Y12 ANTAGONISTS | SANOFI SA (FR) | 2012-08-22 | — | — | EP | disclosed |
| US-20110021537-A1 | HETEROCYCLIC PYRAZOLE-CARBOXAMIDESAS P2Y12 ANTAGONISTS | SANOFI-AVENTIS (FR) | 2011-01-27 | — | — | US | disclosed |
| EP-2238128-A2 | HETEROCYCLIC PYRAZOLE-CARBOXAMIDES AS P2Y12 ANTAGONISTS | Sanofi-Aventis (FR) | 2010-10-13 | — | — | EP | disclosed |
| US-20100135999-A1 | QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS | SANOFI-AVENTIS (FR) | 2010-06-03 | — | — | US | disclosed |
| EP-2148871-A1 | QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS | Sanofi-Aventis (FR) | 2010-02-03 | — | — | EP | disclosed |
| WO-2009080226-A2 | HETEROCYCLIC PYRAZOLE-CARBOXAMIDES AS P2Y12 ANTAGONISTS | SANOFIS-AVENTIS (FR) | 2009-07-02 | — | — | WO | disclosed |
| WO-2008128647-A1 | QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS | SANOFI-AVENTIS (FR) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120277406-A1 | Processes for the Manufacture of Macrocyclic Depsipeptides and New Intermediates | VIP, NPPA, PTMS | ALDH1A1 2965/4885TSHR 2988/4885CTSK 1094/4885 |
| US-20140080995-A1 | Processes for the Manufacture of Macrocyclic Depsipeptides and New Intermediates | VIP, NPPA, PTMS | ALDH1A1 2965/4885TSHR 2988/4885CTSK 1094/4885 |
| US-20100135999-A1 | QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS | P2RY12, P2RY1, P2RY2 | ALDH1A1 2297/4885TSHR 916/4885CTSK 1809/4885 |
| US-20110021537-A1 | HETEROCYCLIC PYRAZOLE-CARBOXAMIDESAS P2Y12 ANTAGONISTS | P2RY1, P2RY12, P2RY11 | ALDH1A1 1179/4885TSHR 1012/4885CTSK 2016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.